Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bleomycin + OK-432 sclerotherapy for intractable lymphatic malformations
jRCTs031180265Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Aug 2016
- Modality
- Small Molecules, Therapeutic Vaccines → Vaccines & Immunotherapeutics, Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of bleomycin and streptococcus pyogenes preparation in lymphangioma and cystic hygroma (CH), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Proportion of subjects with ≥30% reduction in lesion volume. Started Aug 2016; status: completed.
02
Drugs
bleomycinstreptococcus pyogenes preparation
03
Conditions
lymphangiomacystic hygroma (CH)
Beyond the preview
Go deeper on jRCTs031180265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180265.